Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions
Current Oncology · 16.04.2025 · 32 (4) · 232
DOI: 10.3390/curroncol32040232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 16.04.2025. Verfasst von Sushanth Sreenivasan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212, USA. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, and RET receptors. These have facilitated the development of targeted therapies, including TRK inhibitors, HER2-directed agents, and androgen receptor modulators, as well as emerging combinations of immunotherapy and chemotherapy. Despite these advancements, challenges such as resistance mechanisms and limited therapeutic efficacy persist. Overall response rates remain relatively low across most systemic therapies, reflecting a persistent unmet clinical need. This review discusses the current landscape of treatment options and explores promising clinical trials and future directions to enhance outcomes for patients with SGCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212, USA.
- Division of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USA.
ORCID-Profile: Rahim A Jiwani
Zitieren
APA
Sreenivasan, S., Jiwani, R. A., White, R., Bakalov, V., Moll, R., Liput, J., & Greenberg, L. (2025). Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions. Current Oncology, 32(4), 232. https://doi.org/10.3390/curroncol32040232
Vancouver
Sreenivasan S, Jiwani RA, White R, Bakalov V, Moll R, Liput J, et al. Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions. Current Oncology. 2025;32(4):232. doi:10.3390/curroncol32040232
BibTeX
@article{Sreenivasan2025,
author = {Sreenivasan, Sushanth and Jiwani, Rahim A and White, Richard and Bakalov, Veli and Moll, Ryan and Liput, Joseph and Greenberg, Larisa},
title = {Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {4},
pages = {232},
doi = {10.3390/curroncol32040232}
}
EUVIMED